MAIA Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 21.48K shares, a 3668.25% increase year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 570.00 shares, a 99.53% decline from fiscal 2024.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 120.11K shares, a 15914.67% increase from fiscal 2023.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 750.00 shares, a 98.39% decline from fiscal 2022.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 46.50K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 21.48K shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 21.48K shares 10-Q · filed 2026-05-11 | 21.48K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 570.00 shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 2.07K shares derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 18.84K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 570.00 shares 10-Q · filed 2025-05-09 | |
| 2024-12-31 | 1.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | 120.11K shares 10-K · filed 2025-03-21 |
| 2024-09-30 | 16.77K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 750.00 shares 10-K · filed 2024-03-21 |
| 2022-12-31 | 10.00K shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-24 | 46.50K shares 10-K · filed 2023-03-24 |
| 2022-09-30 | 10.00K shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |